Alsebaey Ayman, Ahmedy Eman Aly
Department of Clinical Pathology, Faculty of Medicine, Menoufia University, Shebeen El-Kom, Egypt E-mail :
Asian Pac J Cancer Prev. 2016;17(8):4077-82.
Hepatocellular carcinoma (HCC) is a dreadful complication of end stage liver disease with high morbidity and mortality.
The aim was to assess the role of serum talin-1 and non-invasive brosis in patients with HCC.
A total of eighty seven subjects were enrolled, with 22 two healthy individuals as a control group (n=22), 22 patients in the cirrhosis group and finally 43 in the group with HCC diagnosed with positive triphasic CT abdomen criteria. Serum talin-1 and noninvasive fibrosis parameters were assessed in all subjects.
Compared to the cirrhosis group, patients with HCC had higher serum talin-1 (32.9±12.6 vs. 11.1±2.79 ng/ml), FIB4 (9.96±15.3 vs. 2.90±1.87) and bro-α (10.9±18.1 vs. 1.55±0.28) but not fibrosis index scores (4.47±0.95 vs. 4.98±0.96; p=0.046). Patients with large focal lesions (≥5cm) had different ALBI scores (-1.02±0.63 vs. -1.72±0.59; p=0.001) serum talin-1 (9.72±13.81 vs. 28.6±38.89 ng/ml; p=0.007) and brosis index scores (0.85 ± 0.99 vs. 4.20±4.85; p=0.026). No statistical differences were noted between patients with and without portal vein thrombosis. For detection of HCC, serum talin-1 had 97.7% sensitivity and 100% specificity with a 17.2 ng/ml cutoff. AFP at a 13.7 ng/ml cutoff had 72.1% sensitivity and 6.3.6% specificity. The cutoff for the bro-α score was 1.61 with 81.4% sensitivity and 77.3% specificity. Serum talin-1 (odds=1.08; C.I=1.016-1.150; p=0.014), brosis index score (odds=2.35; C.I=1.055-5.217; p=0.037) and the ALBI score (odds=6.9; C.I=1.924-24.708; p=0.003) were predictors of large focal lesions.
Serum talin-1, AST/ALT ratio, bro-α score are useful for the assessment of HCC patients.
肝细胞癌（HCC）是终末期肝病的一种可怕并发症，发病率和死亡率都很高。
旨在评估血清踝蛋白-1和非侵入性纤维化在HCC患者中的作用。
共纳入87名受试者，其中22名健康个体作为对照组（n = 22），22名肝硬化组患者，最后43名符合腹部三相CT阳性标准诊断为HCC的患者。对所有受试者评估血清踝蛋白-1和非侵入性纤维化参数。
与肝硬化组相比，HCC患者的血清踝蛋白-1（32.9±12.6 vs. 11.1±2.79 ng/ml）、FIB4（9.96±15.3 vs. 2.90±1.87）和纤维化-α（10.9±18.1 vs. 1.55±0.28）更高，但纤维化指数评分无差异（4.47±0.95 vs. 4.98±0.96；p = 0.046）。有大的局灶性病变（≥5cm）的患者具有不同的ALBI评分（-1.02±0.63 vs. -1.72±0.59；p = 0.001）、血清踝蛋白-1（9.72±13.81 vs. 28.6±38.89 ng/ml；p = 0.007）和纤维化指数评分（0.85±0.99 vs. 4.20±4.85；p = 0.026）。有和没有门静脉血栓形成的患者之间未观察到统计学差异。对于HCC的检测，血清踝蛋白-1在截断值为17.2 ng/ml时具有97.7%的敏感性和100%的特异性。AFP在截断值为13.7 ng/ml时具有72.1%的敏感性和6.3.6%的特异性。纤维化-α评分的截断值为1.61，敏感性为81.4%，特异性为77.3%。血清踝蛋白-1（比值=1.08；置信区间=1.016 - 1.150；p = 0.014）、纤维化指数评分（比值=2.35；置信区间=1.055 - 5.217；p = 0.037）和ALBI评分（比值=6.9；置信区间=1.924 - 24.708；p = 0.003）是大的局灶性病变的预测指标。
血清踝蛋白-1、AST/ALT比值、纤维化-α评分有助于评估HCC患者。
